COMMUNIQUÉS West-GlobeNewswire
-
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
29/08/2024 - 14:30 -
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
29/08/2024 - 14:30 -
The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024
29/08/2024 - 14:45 -
Psychemedics Corporation Launches New Ketamine Hair Testing Service
29/08/2024 - 15:00 -
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label
29/08/2024 - 15:00 -
Biomerica Reports Fiscal 2024 Year End Results
29/08/2024 - 15:00 -
Anaptys Announces Participation in September Investor Conferences
29/08/2024 - 15:15 -
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
29/08/2024 - 15:17 -
Major shareholder announcement
29/08/2024 - 15:17 -
iTeos annonce sa participation aux prochaines journées Investisseurs
29/08/2024 - 17:06 -
RAMSAY SANTE : résultats annuels provisoires à fin juin 2024
29/08/2024 - 17:35 -
RAMSAY SANTE : Provisional annual results at the end of June 2024
29/08/2024 - 17:35 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024
29/08/2024 - 18:00 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024
29/08/2024 - 18:00 -
EssilorLuxottica: Succès du placement d'une émission obligataire de 2 milliards d'euros à 2,99 %
29/08/2024 - 19:46 -
EssilorLuxottica: successful Euro 2 billion bond issuance at 2.99%
29/08/2024 - 19:46 -
Radiance BioPharma sponsoring Investor Cruise Event 2024
29/08/2024 - 21:30 -
Cytokinetics to Participate in September Investor Conferences
29/08/2024 - 22:00 -
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/08/2024 - 22:01
Pages